Last reviewed · How we verify

Remicade — Competitive Intelligence Brief

Remicade (infliximab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Oncology.

discontinued Monoclonal antibody TNFα Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Remicade (infliximab) — Johnson & Johnson. Infliximab binds to TNFα, blocking its interaction with receptors, reducing inflammation and immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Remicade TARGET infliximab Johnson & Johnson discontinued Monoclonal antibody TNFα 1998-01-01
Cimzia CERTOLIZUMAB PEGOL UCB marketed Tumor Necrosis Factor Blocker [EPC] TNFα 2008-01-01
Remicade Infliximab-Dyyb Johnson & Johnson marketed TNF blocker Tumor Necrosis Factor alpha (TNFα) 1998-01-01
Infliximab-Dyyb Infliximab-Dyyb Asan Medical Center marketed TNF-alpha inhibitor; monoclonal antibody TNF-alpha (TNFα)
[89Zr]Zr-crefmirlimab berdoxam 89zr-zr-crefmirlimab-berdoxam Pfizer marketed Radiolabeled Monoclonal Antibody Fibroblast Activation Protein (FAP) Not specified
Venetoclax; Rituximab venetoclax-rituximab Pfizer marketed BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab) BCL-2 (venetoclax); CD20 (rituximab) N/A
Hympavzi MARSTACIMAB Pfizer Inc marketed Monoclonal Antibody Factor Xa 2025-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

  1. Pfizer · 7 drugs in this class
  2. argenx · 7 drugs in this class
  3. Johnson & Johnson · 2 drugs in this class
  4. German CLL Study Group · 2 drugs in this class
  5. Amgen · 2 drugs in this class
  6. Hoffmann-La Roche · 2 drugs in this class
  7. Brii Biosciences Limited · 2 drugs in this class
  8. Alexion Pharmaceuticals, Inc. · 2 drugs in this class
  9. Biotest · 2 drugs in this class
  10. Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Remicade — Competitive Intelligence Brief. https://druglandscape.com/ci/infliximab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: